Dr. Piotr Filipczak

Education / Degrees

• 2011: PhD in Medical Sciences, Maria Sklodowska-Curie Institute of Oncology, Gliwice, Poland.
• 2008: MSc in Biotechnology of Plants and Microorganisms, University of Silesia, Katowice, Poland.
• 2006: BSc in General Biotechnology, University of Silesia, Katowice, Poland.

Biography

Before joining the UNM-Valenica Campus, I conducted research at several biomedical institutions including Maria Sklodowska-Curie Institute of Oncology, Harvard Medical School and Lovelace Respiratory Research Institute. My primary research interest focused on novel genes and pathways affecting proliferation and chemoresistance of tumor cells. As a UNM-Valenica faculty, I provide students with instruction in general chemistry and biotechnology classes, both lecture and labs. I also continue my studies on the role of TET1 oncogene in driving malignant phenotype of p53-mutated lung cancers, and on new experimental treatment options for this type of tumor. UNM-Valenica students interested in conducting cancer research can participate in these projects by becoming my research mentees or by enrolling in biotechnology classes (Biol 2710 and 2715) offered at our campus.

Courses Taught

UNM-Valencia Campus:

• Chem 1120C – Introduction to Chemistry Lecture and Laboratory for Non-Majors
• Chem 1215 – General Chemistry I for STEM Majors
• Chem 1215L – General Chemistry I for STEM Majors Laboratory
• Chem 1225 – General Chemistry II for STEM Majors
• Chem 1225L – General Chemistry II for STEM Majors Laboratory
• Biol 2710 – Biotechnology I (Biotechnology Laboratory Techniques I)
• Biol 2715 – Biotechnology II (Biotechnology Laboratory Techniques II)

Selected Publications

• Filipczak PT, Leng S, Tellez CS, Do KC, Grimes MJ, Thomas CL, Walton-Filipczak SR, Picchi MA, Belinsky SA. p53-suppressed oncogene TET1 prevents cellular aging in lung cancer. Cancer Res. 2019;79(8):1758-1768.
• Filipczak PT, Thomas CL, Chen W, Salzman A, McDonald JD, Lin Y, Belinsky SA. TSC2 deficiency unmasks a novel necrosis pathway that is suppressed by the RIP1/RIP3/MLKL signaling cascade. Cancer Res. 2016 Dec;76(24):7130-7139.
• Filipczak PT, Senft AP, Seagrave J, Weber W, Kuehl PJ, Fredenburgh LE, McDonald JD, Baron RM. NOS-2 Inhibition in Phosgene-Induced Acute Lung Injury. Toxicol Sci. 2015 Jul;146(1):89-100. PubMed PMID: 25870319.
• Filipczak PT, Piglowski W, Glowala-Kosinska M, Krawczyk Z, Scieglinska D. HSPA2 overexpression protects V79 fibroblasts against bortezomib-induced apoptosis. Biochem Cell Biol. 2012 Apr;90(2):224-31.

Professional Organizations

• New Mexico Academy of Science, Member.
• UNM Comprehensive Cancer Center, Cellular and Molecular Oncology program, Associate Member.